Network pharmacology‐based investigation to explore the effect and mechanism of Erchen decoction against the nonalcoholic fatty liver disease

Liu, Haiyan; Xu, Jie; Li, Hui; Zhang, Lina; Xu, Peng

doi:10.1002/ar.24770

Cited by 14 publications

(11 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found that the epididymal visceral adipose tissue had larger lipid droplets which is a sign of increased dampness in the body after high-fat diet feed. ECD is clinically used in China to treat obesity and hyperlipidemia by its dampness-reducing effects [12,13]. ECD has been also demonstrated to prevent highfat diet-induced metabolic disorders [23][24][25].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Erchen Decoction Ameliorates the Metabolic Abnormalities of High-Fat Diet-Fed Rats

Cheng

Zhang

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. Brown adipose tissue (BAT) dissipates chemical energy to protect against obesity. In the present study, we aimed to determine the effects of Erchen decoction on the lipolysis and thermogenesis function of BAT in high-fat diet-fed rats. Methods. Sprague-Dawley rats were randomly divided into four groups, which were fed a control diet (C) or a high-fat diet (HF), and the latter was administered with high and low doses of Erchen decoction by gavage once a day, for 12 weeks. Body weight, the serum lipid profile, serum glucose, and insulin levels of the rats were evaluated. In addition, the phosphorylation and protein and mRNA expression of AMP-activated protein kinase (AMPK), adipose triglyceride lipase (ATGL), peroxisome proliferator-activated receptor γ coactivator- (PGC-) 1α, and uncoupling protein 1 (UCP-1) in BAT were measured by immunoblotting and RT-PCR. Results. Erchen decoction administration decreased body weight gain and ameliorated the abnormal lipid profile and insulin resistance index of the high-fat diet-fed rats. In addition, the expression of p-AMPK and ATGL in the BAT was significantly increased by Erchen decoction. Erchen decoction also increased the protein and mRNA expression of PGC-1α and UCP-1 in BAT. Conclusion. Erchen decoction ameliorates the metabolic abnormalities of high-fat diet-fed rats, at least in part via activation of lipolysis and thermogenesis in BAT.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Erchen decoction (ECD) is a common prescription in traditional Chinese medicine (TCM) to treat obesity and its related diseases [ 12 , 13 ]. ECD is composed of Pinellia ternata, tangerine peel, Poria cocos, and Glycyrrhiza uralensis.…”

Section: Introductionmentioning

confidence: 99%

Erchen Decoction Ameliorates the Metabolic Abnormalities of High-Fat Diet-Fed Rats

Cheng

Zhang

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…The prescription consists of Pinellia Ternata (BX) (250 g), Exocarpium Citri Rubrum (JH) (250 g), Poria Cocos (FL) (150 g), and Radix et Rhizoma Glycyrrhizae (GC) (75 g). Relevant studies have shown that ECD has a certain effect on treating metabolic diseases such as hyperlipidemia, diabetes, atherosclerosis, and metabolic syndrome [11][12][13], digestive diseases such as non-alcoholic fatty liver [14], and respiratory diseases [15]. Additionly, ECD can improve both the metabolic syndrome and mental symptoms of a psychopath with schizophrenia [16,17].…”

Section: Introductionmentioning

confidence: 99%

Erchen Decoction regulates AMPK pathway in the treatment of metabolic syndrome induced by second-generation antipsychotics based on network pharmacology and molecular docking strategy

Luo

et al. 2023

Preprint

View full text Add to dashboard Cite

Erchen Decoction(ECD) has been clinically verified to be effective for treating metabolic syndrome(MetS) induced by second-generation antipsychotics(SGAs). Network pharmacology analysis results exhibited that 129 active components and 221 potential targets of ECD, 1027 targets related to MetS, and 361 targets of clozapine and olanzapine were gained after screening. Then, 79 intersection targets of ECD and MetS were obtained by Venn analysis to construct a PPI network. However, it could not explain the potential target and mechanism of ECD to improve the metabolic disorder caused by SGAs. GO function and KEGG pathway analyses were performed on 23 common targets of ECD, clozapine, olanzapine, and metabolic syndrome, and visualization networks were constructed. The results revealed the potential signaling pathway of ECD for treating drug-induced MetS, especially the AMPK signaling pathway. The visualization network reflects that ADRA1A, AHR, NR3C1, and SLC6A4 may be the core targets. Ultimately, molecular docking results displayed that active components of ECD naringenin, baicalein, and quercetin had a good binding activity with NR3C1 and SLC6A4 targets.

show abstract

“…In addition, network analysis played an important role in screening targets of liver disease. For example, the treatment study of Erchen decoction in nonalcoholic fatty liver disease (NAFLD) has shown that the interactions of active ingredients of Erchen decoction with 77 targets related to NAFLD mainly reduces inflammation’s stimulation of the liver through the TLR4 signaling pathway ( Liu et al, 2021 ). Xu et al (2021b) used the network pharmacological method to analyze the mechanism of schisandrol B in the treatment of CCl4-induced liver injury.…”

Section: Introductionmentioning

confidence: 99%

Potential hepatoprotective effects of Cistanche deserticola Y.C. Ma: Integrated phytochemical analysis using UPLC-Q-TOF-MS/MS, target network analysis, and experimental assessment

Wang

Li²,

Bian³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Cistanche deserticola Y.C. Ma (CD) possesses hepatoprotective activity, while the active ingredients and involved mechanisms have not been fully explored. The objective of this study was to investigate the chemical composition and hepatoprotective mechanisms of CD. We primarily used ultra-performance liquid chromatography with quadrupole time-of-flight tandem mass spectrometry (UPLC-Q-TOF-MS/MS) to identify the phenylethanoid glycoside (PhG) components of CD. Then, network analysis was used to correlate and predict the pharmacology of the identified active components of PhGs with hepatoprotection. Next, the mechanisms of the core components and targets of action were explored by cellular assays and toll-like receptor 4 (TLR4) target competition assays. Finally, its hepatoprotective effects were further validated in in vivo experiments. The results showed that a total of 34 PhGs were identified based on the UPLC-Q-TOF-MS/MS method. Echinacoside (ECH) was identified as the key ingredient, and TLR4 and nuclear factor-kappa B (NF-κB) were speculated as the core targets of the hepatoprotective effect of CD via network analysis. The cellular assays confirmed that PhGs had significant anti-inflammatory activity. In addition, the real-time quantitative polymerase chain reaction (RT-qPCR) and Western blot indicated that ECH notably reduced the levels of interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α), as well as the mRNA expression of TLR4, TNF-α, and IL-6, and decreased the high expression of the TLR4 protein, which in turn downregulated the myeloid differentiation factor 88 (MyD88), p-P65 and TNF-α proteins in the inflammatory model. The target competition experiments suggested that ECH and LPS could competitively bind to the TLR4 receptor, thereby reducing the expression of TLR4 downstream proteins. The results of in vivo studies showed that ECH significantly ameliorated LPS-induced hepatic inflammatory infiltration and liver tissue damage and reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in mice. Moreover, ECH remarkably inhibited the release of inflammatory factors such as TNF-α, IL-6, IL-1β, and MCP-1 in the serum of mice, exerting the hepatoprotective effect by the TLR4/NF-κB signaling pathway. More importantly, ECH could act as a potential inhibitor of TLR4 and deserves further in-depth study. Our results could provide a basis for exploring the hepatoprotective properties of CD.

show abstract

Network pharmacology‐based investigation to explore the effect and mechanism of Erchen decoction against the nonalcoholic fatty liver disease

Cited by 14 publications

References 63 publications

Erchen Decoction Ameliorates the Metabolic Abnormalities of High-Fat Diet-Fed Rats

Erchen Decoction Ameliorates the Metabolic Abnormalities of High-Fat Diet-Fed Rats

Erchen Decoction regulates AMPK pathway in the treatment of metabolic syndrome induced by second-generation antipsychotics based on network pharmacology and molecular docking strategy

Potential hepatoprotective effects of Cistanche deserticola Y.C. Ma: Integrated phytochemical analysis using UPLC-Q-TOF-MS/MS, target network analysis, and experimental assessment

Contact Info

Product

Resources

About